Latest News - DexCom
Top Corporates Hub
DexCom
Mizuho Maintains Outperform on DexCom, Raises Price Target to $85
09.06.2026 09:27
Mizuho analyst Anthony Petrone maintains DexCom (NASDAQ:DXCM) with a Outperform and raises the price target from $75 to $85.
DexCom Inc (NASDAQ:DXCM) Passes Rigorous Quality Screen with Strong Profitability and Growth Metrics
08.06.2026 11:10
DexCom (DXCM) excels in quality investing metrics with 11.89% revenue CAGR, 47.12% ROIC, and minimal debt. Strong fundamentals and cash flow make it a standout in diabetes care.
Inspire Medical: Golden Opportunity To Monetize A Fundamentally Mispriced Selloff
08.06.2026 05:08
Inspire Medical Systems faces a sharp revenue slowdown due to temporary CPT coding and CMS Project WISeR disruptions. See why I rate INSP stock a Buy.
DexCom vs. Insulet: Which Diabetes Stock Is a Better Buy in 2026?
04.06.2026 16:10
DexCom posts steady profits and global reach, while Insulet surges ahead with rapid revenue growth and a focused product line. Which strategy stands out?
Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
04.06.2026 13:00
SAN DIEGO, June 04, 2026--DexCom, Inc. (NASDAQ:DXCM) will present new clinical findings, product advancements and strategic business initiatives reinforcing its commitment to improving care for people with all types of diabetes and ushering in a new era of early stage CGM intervention and preventative care at the American Diabetes Association’s Scientific Sessions in New Orleans, June 5-8, 2026.
Did FDA-App Recalls and Activist Pressure Just Rewire Dexcom’s (DXCM) Software-Driven Investment Narrative?
03.06.2026 01:07
In May 2026, Dexcom disclosed FDA-enforced, Class II voluntary recalls of its G7 and ONE/ONE+ iOS and watchOS apps worldwide due to a software defect that can delay or replay glucose readings and alerts, potentially leading users to act on outdated data. The recalls highlight the growing importance of Dexcom’s software quality and real-time data integrity, especially as its CGM ecosystem becomes more deeply embedded in everyday diabetes management across multiple countries and devices. We’ll...
Hims & Hers Expands Benefits for Active Subscribers With Eight New Health and Wellness Partners
28.05.2026 16:00
SAN FRANCISCO, May 28, 2026--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the expansion of Hims & Hers Benefits, adding eight new partners to the Hims & Hers exclusive program. Joining founding partners Prenuvo and Eight Sleep are Natural Cycles, MyFitnessPal, Ladder, PVOLVE Studios, HelloFresh, Factor, Flo Health, Dexcom, and iFIT - a carefully curated lineup spanning nutrition, fitness, women's health, metabolic monitoring, and connected well
U.S.-Iran strikes, Snowflake soars, Robinhood's new AI tools and more in Morning Squawk
28.05.2026 08:00
Here are five key things investors need to know to start the trading day.
How The DexCom (DXCM) Investment Story Is Shifting With New Guidance And Valuation Resets
27.05.2026 15:08
DexCom’s latest valuation work now centers on a fair value anchor of US$81.64, slightly below the prior US$83.54 level and closer to the current range of Street targets. Many firms have trimmed price targets after recent Analyst/Investor Day updates, reflecting a balance between confidence in execution and a more cautious stance on longer term growth and valuation assumptions. As you read on, you will see how these shifting targets, together with fresh guidance and product news, shape the...
Signos grows foothold in weight loss wave fueled by GLP-1s with its AI health data tracking
27.05.2026 09:07
Health tech startup Signos announced a $20 million funding round Wednesday, including an expanded partnership with medical device giant Dexcom.
Dexcom Uncovers Theft of Scrapped Product, Notifies Potentially Impacted Users
26.05.2026 13:30
SAN DIEGO, May 26, 2026--DexCom, Inc. (Nasdaq: DXCM), the global leader in glucose biosensing, announced today through ongoing quality and accounting reviews it recently identified certain lots of Dexcom G7 sensors originally designated as scrap and intended for destruction were stolen during the destruction process, then sold by third parties.
DXCM to Launch Dexcom Flex CGM System for Type 2 Diabetes in Germany
19.05.2026 14:55
DexCom gains 5.6% after announcing plans to launch Dexcom Flex in Germany, expanding CGM access for Type 2 diabetes patients using basal insulin or oral meds.
14. OURA
19.05.2026 05:55
OURA, at the center of the tracking of the health and wellness boom, ranks No. 14 on CNBC’s 2026 Disruptor 50 list.
Redefining CGM for People With Type 2 Diabetes: Dexcom Announces Dexcom Flex in Germany
18.05.2026 11:31
SAN DIEGO & EDINBURGH, Scotland, May 18, 2026--DexCom, Inc. (Nasdaq: DXCM), a global leader in continuous glucose monitoring, today announced Dexcom Flex, a new CGM system designed specifically for adults with Type 2 diabetes who are not using intensive insulin therapy. The new system will be available in Germany soon.
Did New Long-Term Targets and US$1 Billion Buyback Just Shift DexCom's (DXCM) Investment Narrative?
17.05.2026 05:14
Earlier this week, DexCom held its 2026 Investor Day, outlining long-term targets for at least 10% annual organic revenue growth through 2030, plans for margin expansion, and a new US$1.00 billion share repurchase program running until June 30, 2027, following the completion of its prior US$500.00 million buyback. At the same time, DexCom announced governance changes, including working with activist investor Elliott Investment Management to add two independent directors and create an...
DexCom Maps G8 Launch, Coverage Expansion and Double-Digit Growth at Investor Day
16.05.2026 13:08
DexCom (NASDAQ:DXCM) used its 2026 Investor Day to outline a long-range plan centered on new product launches, broader insurance coverage for continuous glucose monitoring, international expansion and margin improvement. President and Chief Executive Officer Jake Leach said the company’s next phase
DexCom (DXCM) Posts Upbeat 2026, Climbs 6.6%
16.05.2026 01:43
DexCom Inc. (NASDAQ:DXCM) is one of the 10 Stocks Dominating With Powerful Gains. DexCom snapped a two-day loss on Friday, jumping 6.59 percent to close at $61.63 apiece, as investor sentiment was bolstered by its higher growth outlook for the full-year period. At its investor day on Thursday, DexCom Inc. (NASDAQ:DXCM) announced an organic revenue […]
DexCom, Inc. announces an Equity Buyback for $1,000 million worth of its shares.
15.05.2026 09:05
DexCom, Inc. announces a share repurchase program. Under the program, the company will repurchase up to $1,000 million worth of its shares. The plan will be valid till June 30, 2027....
Tranche Update on DexCom, Inc.'s Equity Buyback Plan announced on May 1, 2025.
15.05.2026 09:05
From January 1, 2026 to May 14, 2026, the company has repurchased 75 shares, representing 0.000019% for $0.005036 million. With this, the company has completed the repurchase of 7,669,071 shares,...
Is DexCom (DXCM) Share Weakness Creating A Valuation Opportunity For Investors?
13.05.2026 10:28
If you are wondering whether DexCom's current share price still reflects its potential, the recent valuation signals give you plenty to think about. The stock closed at US$61.14, with a gain of 2.8% over the last week, while returns over the last month, year to date, and past year show declines of 4.5%, 8.1%, and 27.3% respectively. Over three and five years the stock is down 48.5% and 25.9%. These moves have kept DexCom firmly on investors' watchlists, with ongoing attention on how...